Covid-19 (Temas de Saúde Pública)

[Preprint] Estudo de coorte | Risco reduzido de internação associado com infecção pela variante Ômicron do SARS-CoV-2 em relação à variante Delta.

25 Jan, 2022 | 15:01h

Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study – SSRN / Preprints with The Lancet

Comentários:

Danish report: lower risk of hospitalisation with Omicron – Copenhagen Post

Omicron has a 36% lower risk for hospitalization compared to Delta: Denmark study – Outbreak News Today

 

Comentário no Twitter

New Danish population-based cohort study confirms lower (36%, 95%CI 44%-25%) risk of hospitalization with Omicron compared with Delta.
The risk also seems to be reduced irrespective of vaccination status.

Pre-print can be found here: https://t.co/LfRrw1H3CY pic.twitter.com/Ql3zPyZyRE

— Anders Husby (@a_husby) January 20, 2022

 

---

[Preprint] A variante Ômicron do SARS-CoV-2 está associada com risco reduzido de internação e permanência em hospital, em comparação com a variante Delta.

25 Jan, 2022 | 14:59h

Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2) – medRxiv

 

Comentário no Twitter

In Portugal, Omicron hospitalizations were 75% reduced compared with Delta, risk adjusted. Vaccination reduced hospitalizations 84%, w/a booster 93%https://t.co/MvkfuF3mzx pic.twitter.com/zyk2INWNis

— Eric Topol (@EricTopol) January 23, 2022

 

---

COVID-19: endemia não significa que o risco acabou.

25 Jan, 2022 | 14:58h

COVID-19: endemic doesn’t mean harmless – Nature

---

Diretor geral da OMS | “Vamos conviver com a COVID em futuro previsível; mas podemos acabar com a fase aguda da pandemia este ano.”

25 Jan, 2022 | 14:57h

We Will be Living with COVID for Foreseeable Future; but We Can End Acute Phase of Pandemic this Year — WHO Director General – Health Policy Watch

---

Estudo de caso-controle | 3 doses de vacinas de mRNA foram associadas com redução nas infecções pelas variantes Ômicron e Delta do SARS-CoV-2 em comparação com 2 doses ou nenhuma vacinação.

25 Jan, 2022 | 12:07h

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants – JAMA

Editorial: Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach – JAMA

Comentários: New data show booster doses protect against Omicron – CIDRAP

Boosters provide the best protection against Omicron variant, CDC studies show, raising new questions about what it means to be fully vaccinated – CNN

Estudos do CDC relacionados:

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 – CDC Morbidity and Mortality Weekly Report

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

 

Comentário no Twitter

Study suggests receipt of 3 doses of mRNA #COVID19 vaccine, vs 2 doses or being unvaccinated, was associated with protection against both the Omicron and Delta variants; higher odds ratios for Omicron suggest less protection for Omicron than for Delta. https://t.co/kOZh0fq5TL

— JAMA (@JAMA_current) January 21, 2022

 

---

CDC da Europa sobre a Ômicron: “Entre os casos de Ômicron reportados ao TESSy, 1,14% foram internados, 0,16% necessitaram de internação em UTI/suporte respiratório e 0,06% morreram.”

25 Jan, 2022 | 12:05h

Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA – European Centre for Disease Prevention and Control (ECDC)

---

Roteiro atualizado da OMS para priorizar o uso das vacinas contra COVID-19.

25 Jan, 2022 | 12:03h

WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines – World Health Organization

Comentário: WHO: COVID boosters should start with most vulnerable – Associated Press

 

Comentário no Twitter (fio – clique para saber mais)

UPDATED: The Strategic Advisory Group of Experts (SAGE) have revised the Roadmap for Prioritising Uses of #COVID19 vaccines.

👉 https://t.co/FJFlMpBSSK pic.twitter.com/4SNH7ZpSwz

— World Health Organization (WHO) (@WHO) January 21, 2022

 

---

Resumo técnico da OMS | Aprimorando a resposta à variante Ômicron do SARS-CoV-2.

25 Jan, 2022 | 12:01h

Enhancing response to Omicron SARS-CoV-2 variant – World Health Organization

---

Conselheiros da OMS analisam os reforços das vacinas contra COVID-19 e a vacina da Pfizer para crianças pequenas.

25 Jan, 2022 | 12:00h

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids – CIDRAP

Ver também: Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing – World Health Organization

---

Voos na era COVID-19: avaliação de risco baseada em ciência e estratégias de mitigação em solo e no ar.

25 Jan, 2022 | 11:58h

Flying in the COVID-19 Era: Science-based Risk Assessments and Mitigation Strategies on the Ground and in the Air – National Academies of Sciences, Engineering, and Medicine (necessário cadastro gratuito)

---